Regal Investment Advisors LLC boosted its holdings in shares of Aurora Cannabis Inc (NYSE:ACB) by 25.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 44,810 shares of the company’s stock after purchasing an additional 8,999 shares during the quarter. Regal Investment Advisors LLC’s holdings in Aurora Cannabis were worth $350,000 at the end of the most recent quarter.
Other large investors have also recently added to or reduced their stakes in the company. Moisand Fitzgerald Tamayo LLC bought a new stake in Aurora Cannabis in the 1st quarter worth approximately $25,000. Financial Management Professionals Inc. increased its position in shares of Aurora Cannabis by 586.3% during the 1st quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock valued at $28,000 after purchasing an additional 2,615 shares during the last quarter. Carroll Financial Associates Inc. bought a new position in shares of Aurora Cannabis during the 1st quarter valued at approximately $27,000. Burt Wealth Advisors increased its position in shares of Aurora Cannabis by 1,033.3% during the 1st quarter. Burt Wealth Advisors now owns 3,400 shares of the company’s stock valued at $31,000 after purchasing an additional 3,100 shares during the last quarter. Finally, Mackey Komara & Dankovich LLC bought a new position in shares of Aurora Cannabis during the 2nd quarter valued at approximately $27,000. 9.04% of the stock is currently owned by institutional investors and hedge funds.
ACB traded down $0.24 during trading hours on Friday, reaching $6.40. 167,986 shares of the company’s stock traded hands, compared to its average volume of 14,985,294. The company’s 50-day moving average price is $7.01. Aurora Cannabis Inc has a 52-week low of $4.05 and a 52-week high of $12.52. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.37 and a quick ratio of 1.98. The firm has a market capitalization of $6.95 billion, a price-to-earnings ratio of 53.37 and a beta of 2.44.
Several equities analysts have recently weighed in on ACB shares. LADENBURG THALM/SH SH started coverage on Aurora Cannabis in a research report on Wednesday, July 17th. They set a “buy” rating and a $9.00 target price on the stock. Desjardins started coverage on Aurora Cannabis in a research report on Thursday, April 25th. They set a “buy” rating and a $9.07 target price on the stock. Stifel Nicolaus started coverage on Aurora Cannabis in a research report on Wednesday, June 5th. They set a “hold” rating on the stock. Compass Point started coverage on Aurora Cannabis in a research report on Monday, July 8th. They set a “neutral” rating on the stock. Finally, Bank of America downgraded Aurora Cannabis from a “buy” rating to a “neutral” rating and set a $7.30 target price on the stock. in a research report on Thursday, July 18th. Five analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $8.47.
Aurora Cannabis Profile
Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.